Switching to tildrakizumab for moderate to severe psoriasis
Treatments studied
Part of Skin clinical trials.
This trial is for adults with moderate to severe plaque psoriasis who are currently on a biologic treatment (like Humira, Stelara, or Cosentyx) and are switching to tildrakizumab. It looks at how your quality of life and symptoms change after the switch.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have moderate to severe plaque psoriasis
- You are currently being treated with a biologic medicine (TNFα blocker, IL12/23 blocker, or IL17 blocker)
- You are switching to tildrakizumab because your current biologic isn't working well enough, you had side effects, it's not safe for you, or you prefer a different dosing schedule
- You have not already been treated with tildrakizumab
- You have not used 3 or more different biologic medicines in the past 3 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.